DalsnaFinance › Analyst accuracy › H.C. Wainwright › RARE target
Wells Fargo raises Ultragenyx Pharma price target on phase 3 data
H.C. Wainwright reiterated its Buy rating with a $50 price target
A fact about what H.C. Wainwright published, as reported by Investing.com, not a recommendation from Dalsna Finance; H.C. Wainwright is not affiliated with this site.
Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.